Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Income from Continuing Operations (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Income from Continuing Operations for 4 consecutive years, with 21143000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 71.62% to 21143000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 221058000.0 through Dec 2025, up 33.88% year-over-year, with the annual reading at 221057000.0 for FY2025, 33.88% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 21143000.0 at Phathom Pharmaceuticals, up from 29966000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 21143000.0 in Q4 2025, with the low at 94294000.0 in Q1 2025.
  • Average Income from Continuing Operations over 4 years is 59649562.5, with a median of 53018500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 123.2% in 2024, then soared 71.62% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 54957000.0 in 2022, then tumbled by 44.76% to 79556000.0 in 2023, then rose by 6.36% to 74500000.0 in 2024, then skyrocketed by 71.62% to 21143000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 21143000.0, 29966000.0, and 75655000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.